IRD
HEALTHCAREOpus Genetics, Inc.
AI Insight
What's Moving IRD Today?
No stock-specific AI insight has been generated for IRD yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.90$5.81
$4.08
Fundamentals
Market Cap$337M
P/E Ratio—
EPS$-1.31
Dividend Yield—
Dividend / Share—
ROE-7,595.0%
Profit Margin—
Debt / Equity—
Trading
Volume727K
Avg Volume (10D)—
Shares Outstanding82.6M
IRD News
20 articles- Opus Genetics Highlights Five Gene Therapy Programs Targeting Significant Unmet Need in Patients with Inherited Retinal DiseasesYahoo Finance·Jun 16, 2026
- Guggenheim Initiates Coverage Of Opus Genetics (IRD) With “Buy” Rating And $16 Price TargetYahoo Finance·Jun 10, 2026
- Opus Genetics to Host Virtual R&D Science Forum on Tuesday, June 16, 2026 Featuring Multiple Inherited Retinal Disease ExpertsYahoo Finance·Jun 2, 2026
- Opus Genetics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Yahoo Finance·May 28, 2026
- Opus Genetics to Present at the 2026 Jefferies Global Healthcare ConferenceYahoo Finance·May 27, 2026
- Opus Genetics Touts Retinal Gene Therapy Pipeline, September BEST1 Data CatalystMarketbeat·May 26, 2026
- Opus Genetics to Present at the RBC Capital Markets 2026 Global Healthcare ConferenceYahoo Finance·May 13, 2026
- Opus Genetics, Inc. (IRD) Reports Q1 Loss, Misses Revenue EstimatesYahoo Finance·May 12, 2026
- Opus Genetics Announces Financial Results for First Quarter 2026 and Provides Corporate UpdateYahoo Finance·May 12, 2026
- Certara, Inc. (CERT) Q1 Earnings Miss EstimatesYahoo Finance·May 11, 2026
- Opus Genetics Presents Clinical and Preclinical Data at ARVO 2026 Demonstrating Continued Pipeline Advancement in Inherited Retinal DiseasesYahoo Finance·May 7, 2026
- Opus Genetics Completes Enrollment in Cohort 1 of Phase 1/2 OPGx-BEST1 Gene Therapy StudyYahoo Finance·May 7, 2026
- Here is Why Opus Genetics (IRD) is One of the Best Performing NASDAQ StocksYahoo Finance·May 5, 2026
- Opus Genetics Announces FDA Acceptance of OPGx-LCA5 into Rare Disease Evidence Principles (RDEP) ProgramYahoo Finance·May 4, 2026
- Citizens Initiates Coverage of Opus Genetics (IRD)Yahoo Finance·May 1, 2026
- Opus Genetics to Participate in Leading Medical Conferences in May 2026Yahoo Finance·Apr 27, 2026
- Opus Genetics Announces Data Presentations at the 2026 American Society of Cataract and Refractive Surgery Annual MeetingGlobeNewswire Inc.·Apr 10, 2026
- Opus Genetics Solidifies Leadership Position in Gene Therapy Development for Inherited Retinal Diseases with Strategic Long-Term Financing by Oberland CapitalGlobeNewswire Inc.·Apr 6, 2026
- Opus Genetics Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2026Yahoo Finance·Mar 24, 2026
- BTIG Raises its Price Target on Opus Genetics, Inc. (IRD) to $12 from $7 and Maintains a Buy RatingYahoo Finance·Mar 12, 2026
All 20 articles loaded
Price Data
Open$4.03
Previous Close$4.08
Day High$4.29
Day Low$4.03
52 Week High$5.81
52 Week Low$0.90
52-Week Range
$0.90$5.81
$4.08
Fundamentals
Market Cap$337M
P/E Ratio—
EPS$-1.31
Dividend Yield—
Dividend / Share—
ROE-7,595.0%
Profit Margin—
Debt / Equity—
Trading
Volume727K
Avg Volume (10D)—
Shares Outstanding82.6M
About Opus Genetics, Inc.
Opus Genetics, Inc. (IRD) is a leading biotechnology firm focused on developing innovative gene therapies for rare retinal diseases impacting vision. By leveraging advanced gene-editing technologies and a robust research foundation, Opus aims to fulfill critical unmet medical needs in ocular health. With a promising pipeline supported by active clinical trials and strategic collaborations, the company is well-positioned to make significant contributions to patient care while presenting compelling growth opportunities for institutional investors in the dynamic healthcare landscape.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeCommon Stock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—